Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 5/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | RUNX1 | Q01196 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 4/20 | 0.37 |
| ▸ | GPR3 | P46089 | 2/20 | 0.35 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5793465 | 0.96 | CRHR1 (0.52) | CRHR1SCN9ARUNX1ABL1GPR3 | |
| SCHEMBL6286387 | 0.79 | CRHR1 (0.61) | CRHR1SCN9ARUNX1GPR3 | |
| SCHEMBL5796326 | 0.78 | CRHR1 (0.49) | CRHR1SCN9ARUNX1GPR3 | |
| SCHEMBL5794036 | 0.77 | CRHR1 (0.58) | CRHR1SCN9ARUNX1 | |
| SCHEMBL5751614 | 0.73 | CRHR1 (0.58) | CRHR1SCN9ARUNX1ABL1GPR3 | |
| SCHEMBL5768322 | 0.72 | CRHR1 (0.48) | CRHR1KDM4EALDH1A1 | |
| SCHEMBL5797389 | 0.71 | CRHR1 (0.54) | CRHR1SCN9A | |
| SCHEMBL5752602 | 0.71 | CRHR1 (0.53) | CRHR1SCN9ARUNX1ABL1GPR3 | |
| SCHEMBL4924779 | 0.71 | CRHR1 (0.58) | CRHR1SCN9AADORA3 | |
| SCHEMBL5438286 | 0.70 | CRHR1 (0.45) | CRHR1SCN9ARUNX1ABL1GPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675858-A2 | 5-ARYL-PYRAZOLO [4,3-D] PYRIMIDINES, PYRIDINES, AND PYRAZINES AND RELATED COMPOUNDS | NEUROGEN CORPORATION (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005028480-A2 | 5-ARYL-PYRAZOLO[4,3-D]PYRIMIDINES, PYRIDINES, AND PYRAZINES AND RELATED COMPOUNDS | NEUROGEN CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20050070542-A1 | 5-Aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds | NEUROGEN CORPORATION | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070542-A1 | 5-Aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds | CRHR1, HTR5A, HTR1D | CRHR1 1/4885SCN9A 4527/4885RUNX1 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.